24 results found.

Glioma Clinical Trial using temozolomide (TMZ); bevacizumab [Avastin]; Radiotherapy

Hoffmann-La Roche - Recruiting 6 Months to 18 years.
- A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, Or Peduncular High-Grade Glioma.
temozolomide (TMZ); bevacizumab [Avastin]; Radiotherapy

Glioblastoma, Glioma Clinical Trial using GDC-0084

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma.
GDC-0084

Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendrogliom Clinical Trial using Toca 511; 5-FC

Tocagen Inc. - Recruiting 18 years or older.
- A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma.
Toca 511; 5-FC

Malignant Glioma Clinical Trial using 18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide

Dr. Negrin University Hospital - Recruiting 18 years to 75 years.
- Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation.
18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide

Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, or High Clinical Trial using Lenalidomide; Radiation Therapy

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 21 years.
- A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas.
Lenalidomide; Radiation Therapy

Glioma, Glioblastoma, or Brain Tumor, Recurrent Clinical Trial using ANG1005; Bevacizumab

Angiochem Inc - Recruiting 18 years or older.
- A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma.
ANG1005; Bevacizumab

Diffuse Intrinsic Pontine Glioma, or High-grade Glioma Clinical Trial using Chemotherapy

St. Jude Children's Research Hospital - Recruiting 2 years to 21 years.
- Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG).
Chemotherapy

Brain and Central Nervous System Tumors Clinical Trial using mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment.
mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study

High Grade Glioma Clinical Trial

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas.

Glioma Clinical Trial using 5-Aminolevulinic acid (ALA); Placebo - ascorbic acid

St. Joseph's Hospital and Medical Center, Phoenix - Recruiting 18 years or older.
- Barrow 5-ALA Intraoperative Confocal Evaluation Trial.
5-Aminolevulinic acid (ALA); Placebo - ascorbic acid

Glioblastoma, Malignant Glioma, Brain Tumors, or Anaplastic Astro Clinical Trial using Stem Cell Radiotherapy (ScRT) and Temozolomide

Beth Israel Medical Center - Recruiting 18 years to 70 years.
- STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial.
Stem Cell Radiotherapy (ScRT) and Temozolomide

Brain Neoplasm, or Glioma Clinical Trial using IL13-PE38QQR

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 17 years.
- An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma.
IL13-PE38QQR

Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood A Clinical Trial using oncolytic HSV-1716; dexamethasone; therapeutic conventional surgery; laboratory biomarker analysis

Pediatric Brain Tumor Consortium - Recruiting 16 years to 21 years.
- A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG).
oncolytic HSV-1716; dexamethasone; therapeutic conventional surgery; laboratory biomarker analysis

Malignant Glioma, or Glioblastoma Clinical Trial using External beam radiotherapy

Rigshospitalet, Denmark - Recruiting 18 years or older.
- Image Guided Reirradiation of High-grade Glioma - a Phase I/II Dose Escalation Study.
External beam radiotherapy

High Grade Glioma Clinical Trial using FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

Brigham and Women's Hospital - Recruiting 18 years to 85 years.
- Personalized Translational Platform for Biomarker Discovery in Brain Tumors.
FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

HIGH GRADE GLIOMA Clinical Trial using TH-302; Placebo

The University of Texas Health Science Center at San Antonio - Recruiting 18 years or older.
- A Phase 2, Investigator Initiated Study to Determine the Safety, Efficacy and CNS Penetration of TH-302 in Recurrent High Grade Astrocytoma Following Bevacizumab.
TH-302; Placebo

Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Clinical Trial using vorinostat; bevacizumab; temozolomide

National Cancer Institute (NCI) - Recruiting 3 years to 21 years.
- A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas.
vorinostat; bevacizumab; temozolomide

Medulloblastoma,, Rhabdomyosarcoma,, Neuroblastoma,, Hepatoblasto Clinical Trial using LDE225

Novartis - Recruiting 12 Months to 18 years.
- A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma.
LDE225

Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 13 years or older.
- Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, or Hi Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 1 year to 30 years.
- A Phase I Study of Dendritic Cell Vaccine Therapy With In Situ Maturation for Pediatric Brain Tumors.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

Newly Diagnosed High-Grade Glioma Clinical Trial using Mebendazole

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase I Study of Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide.
Mebendazole

Brain Neoplasms, Primary Malignant Clinical Trial

Universitaire Ziekenhuizen Leuven - Recruiting 18 years or older.
- Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers.

High-grade Glioma of the Brain Clinical Trial using PET images with 18F-fluoromethylcholine

University Ghent - Recruiting 18 years or older.
- PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?.
PET images with 18F-fluoromethylcholine

Glioma Clinical Trial using Temozolomide and Bevacizumab

Kentuckiana Cancer Institute - Recruiting 18 years to 75 years.
- A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma.
Temozolomide and Bevacizumab